Uncategorized

ROCHESTER, Minn., July 18, 2018 – Vyriad Inc., a clinical-stage, privately held biotechnology company focused on the development of powerful first-in class oncolytic virotherapies, is pleased to announce a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to expand its ongoing Phase 1 clinical...

.entry_title .date { display: none; } p { font-size: 16px; margin: 1em 0 1em 30%; } .intro { font-size: 24px; color: #000; margin: 1em 0 1em 30%; } .photo { margin-right: 30%; } ul p { margin: 0 0 0 30% !important; } ul li { margin-bottom: 1em; } ul p a { font-size: 16px; } @media screen and (max-width: 767px) { p { font-size: 16px; margin: 1em 0 1em 0;...

Combination of Tessa’s Virus Specific T cell (VST) platform and Vyriad’s oncolytic viruses are highly synergistic and have the potential to effectively target a broad range of hard-to-treat solid tumors   SINGAPORE – 25 April 2017 – Tessa Therapeutics, an immunotherapy company dedicated to revolutionizing the treatment...

ROCHESTER, Minn., August 16, 2016 — Vyriad announced today the signing of a license collaboration agreement with Imanis Life Sciences to develop in vitro and in vivo theranostic tests that assess the probability that a cancer patient will be responsive to Vyriad's oncolytic virus therapeutics. The...

– Company secures equity position in StingInn, LLC – ROCHESTER, Minn., August 5, 2016 — Vyriad today announced an exclusive global license agreement with StingInn, LLC for StingInn’s STING oncolytic virus technology for use in Vyriad’s oncolytic virotherapy product candidates for the treatment of advanced-stage cancers....